Dr. Sonpavde on the Biggest Challenges in Bladder Cancer

Guru P. Sonpavde, MD
Published: Wednesday, Jul 17, 2019



Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the biggest challenges in the field of bladder cancer.

Bladder cancer is a heterogeneous disease driven by many pathways and molecules, explains Sonpavde. As such, there is no predominant target. This has been an impediment to improving cure rates. However, these challenges have, in part, been addressed with immunotherapy. Bladder cancer has a high mutation burden, which has enabled advances with this approach.

Combinations of immunotherapy drugs might further enhance the benefit that has been observed to date. There are many ongoing phase I trials looking at these combinations, many of which are open at Dana-Farber Cancer Institute. Sonpavde is hopeful that these combinations will take treatment of the disease to the next level.
SELECTED
LANGUAGE


Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the biggest challenges in the field of bladder cancer.

Bladder cancer is a heterogeneous disease driven by many pathways and molecules, explains Sonpavde. As such, there is no predominant target. This has been an impediment to improving cure rates. However, these challenges have, in part, been addressed with immunotherapy. Bladder cancer has a high mutation burden, which has enabled advances with this approach.

Combinations of immunotherapy drugs might further enhance the benefit that has been observed to date. There are many ongoing phase I trials looking at these combinations, many of which are open at Dana-Farber Cancer Institute. Sonpavde is hopeful that these combinations will take treatment of the disease to the next level.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x